Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

RaysightMed Secures Nearly RMB 100 Million in Strategic Financing Led by State-Owned Capital – Accelerates Cardiovascular Diagnostics Scale-Up and AI Surgical Robotics Development

Fineline Cube Jul 1, 2026
Company Deals

Ribo Life Science Acquires Additional 25.93% Stake in Azemidite for RMB 70 Million – Strengthens siRNA Therapeutics Supply Chain

Fineline Cube Jul 1, 2026
Company Deals

METiS TechBio Signs Record $1.62B Global Licensing Deal for AI-Designed Tri-Specific TCE MTS-128 – Largest Preclinical TCE Out-Licensing by Chinese Pharma Company

Fineline Cube Jun 30, 2026
Company Deals

Eli Lilly Partners with Innovent Biologics on Verzenio CDK4/6 Inhibitor – Chinese Biotech Secures Exclusive Commercialization Rights in Mainland China

Fineline Cube Jun 30, 2026
Company Deals

Qyuns Therapeutics to Acquire Remaining 34% Stake in CMC Subsidiary Cellularforce for RMB 86M – Full Ownership Secures NDA Pathway for IL-17A and IL-4Rα Antibody Pipeline

Fineline Cube Jun 30, 2026
Policy / Regulatory

China’s CDE Unveils 108th Batch of Reference Preparations for Generic Drug Evaluation, Adds 28 New Drugs

Fineline Cube Jun 29, 2026
Company Drug

Hybio Pharma’s Generic Tirzepatide ANDA Accepted by FDA – First-to-File Challenger Targets $20B+ Dual GLP-1/GIP Agonist Franchise with Paragraph IV Certification

Fineline Cube Jul 1, 2026
Company Drug

Roche Receives FDA Priority Review for Enspryng in Thyroid Eye Disease – IL-6 Inhibitor Leverages Novel Recycling Technology for Second Indication

Fineline Cube Jul 1, 2026
Company Policy / Regulatory

Shaanxi Releases Notice for Inter-Provincial Orthodontic Brackets VBP

Fineline Cube Oct 20, 2022

The Shaanxi Public Resources Trading Center has released the “Inter-provincial Alliance (regions, Corps) Orthodontic Brackets...

Company Drug

Hainan Poly Pharm’s Generic Ganciclovir Approved in Sweden for CMV Retinitis

Fineline Cube Oct 20, 2022

China-based Hainan Poly Pharm Co., Ltd (SHE: 300630) has announced receiving technical review approval from...

Company Drug

Bio-Thera’s BAT1806 Biosimilar Accepted for Review by European Medicine Agency

Fineline Cube Oct 20, 2022

China-based Bio-Thera Solutions Ltd (SHA: 688177) has announced that a Biologic License Application (BLA) for...

Company Deals

Kactus Biosystems Raises RMB 200M in Series B Financing for Protein and Enzyme Development

Fineline Cube Oct 20, 2022

Kactus Biosystems, a Shanghai-based firm specializing in target proteins and raw enzymes, has raised RMB...

Company Deals

Shandong Junxiu Biotechnology Secures RMB 45M in Series B Financing

Fineline Cube Oct 20, 2022

Shandong Junxiu Biotechnology Co., Ltd, a China-based maker of implantable regenerative medicine devices, has raised...

Company Drug

Brii Biosciences Reports Positive Phase I Results for HIV Treatments BRII-732 and BRII-778

Fineline Cube Oct 20, 2022

China-based Brii Biosciences Limited (HKG: 2137) has published the latest results of two Phase I...

Company

Bayer to Set Up Shenzhen Unit to Boost Women’s Healthcare in South China

Fineline Cube Oct 19, 2022

Bayer’s (ETR: BAYN) women’s healthcare unit for the South China region is reportedly planning to...

Company Drug

GenScript’s Legend Biotech Reports USD 55M in Carvykti Sales

Fineline Cube Oct 19, 2022

China-based Contract Research Organization (CRO) GenScript Biotech Corporation (HKG: 1548) has revealed that sales of...

Company Drug

YiChang HEC ChangJiang Pharma’s Insulin Aspart Gains NMPA Approval

Fineline Cube Oct 19, 2022

China-based firm YiChang HEC ChangJiang Pharmaceutical Co., Ltd (HKG: 1558) has announced that its in-house...

Company Drug

Henlius Biotech’s Hanbeitai Gains NMPA Approval for Recurrent Glioblastoma

Fineline Cube Oct 19, 2022

Shanghai Henlius Biotech Inc. (HKG: 2696) has announced that a supplementary Biologic License Application (sBLA)...

Company Policy / Regulatory

NHSA Responds to Proposal on Dental Implants’ Inclusion in NRDL

Fineline Cube Oct 19, 2022

The National Healthcare Security Administration (NHSA) has responded to the No. 6184 suggestion from the...

Company

Johnson & Johnson Reports Q3 Sales Growth, Maintains Full-Year Guidance

Fineline Cube Oct 19, 2022

US giant Johnson & Johnson (J&J, NYSE: JNJ) released its Q3 2022 financial report, showing...

Company Deals

Sichuan Biokin Pharma Plans IPO on STAR Board to Raise RMB 1.422 Billion

Fineline Cube Oct 19, 2022

China-based Sichuan Biokin Pharmaceutical Co., Ltd is set to conduct an initial public offering (IPO)...

Company Drug

Mabwell Bioscience’s 9MW3011 Accepted for Review by China’s NMPA

Fineline Cube Oct 19, 2022

China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) has announced that its clinical filing for...

Company Drug

Zhiyi Biotechnology Receives FDA Clearance for SK10 in Chemotherapy-Induced Diarrhea

Fineline Cube Oct 19, 2022

Guangzhou-based Zhiyi Biotechnology has announced receiving clearance from the US FDA for a clinical study...

Company Deals

Shanghai’s Hrain Biotechnology Plans IPO on STAR Board to Raise RMB 2.539 Billion

Fineline Cube Oct 19, 2022

Shanghai-based Hrain Biotechnology Co., Ltd, a specialist in tumor immunotherapy, plans to conduct an initial...

Company Deals

Eucure Biopharma Partners with Syncromune on Intratumoral Immunotherapy

Fineline Cube Oct 18, 2022

Eucure Biopharma, a wholly-owned subsidiary of Sino-US contract research organization (CRO) Biocytogen, has entered into...

Company Drug

Abogen Biosciences Receives UAE Clinical Trial Approval for Omicron BA.4/5 mRNA Vaccine

Fineline Cube Oct 18, 2022

China’s Abogen Biosciences Co., Ltd, a developer of messenger ribonucleic acid (mRNA) drugs, has announced...

Company Deals

Shenzhen GeneBioHealth Secures USD 15M for Bio-Business Expansion

Fineline Cube Oct 18, 2022

Shenzhen GeneBioHealth Co., Ltd, a China-based in-vitro diagnostic (IVD) medical device developer, has reportedly raised...

Company Drug

CSPC’s Generic Xofluza Gains NMPA Approval Amid Roche Patent Dispute

Fineline Cube Oct 18, 2022

China-based CSPC Pharmaceutical Group Co., Ltd (HKG: 1093) has obtained market approval from the National...

Posts pagination

1 … 636 637 638 … 689

Recent updates

  • Hybio Pharma’s Generic Tirzepatide ANDA Accepted by FDA – First-to-File Challenger Targets $20B+ Dual GLP-1/GIP Agonist Franchise with Paragraph IV Certification
  • Roche Receives FDA Priority Review for Enspryng in Thyroid Eye Disease – IL-6 Inhibitor Leverages Novel Recycling Technology for Second Indication
  • Huiyu Pharma Receives NMPA Clinical Trial Approval for HY-1016 Extended-Release Dienogest Injection – Novel Formulation Aims to Transform Endometriosis Treatment Adherence
  • RaysightMed Secures Nearly RMB 100 Million in Strategic Financing Led by State-Owned Capital – Accelerates Cardiovascular Diagnostics Scale-Up and AI Surgical Robotics Development
  • CSPC Innovation Launches Phase III Trial of SYS6010 ADC-PD-1 Combo in Resected NSCLC – Novel EGFR-Targeted Antibody-Drug Conjugate Enters Adjuvant Setting
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Hybio Pharma’s Generic Tirzepatide ANDA Accepted by FDA – First-to-File Challenger Targets $20B+ Dual GLP-1/GIP Agonist Franchise with Paragraph IV Certification

Company Drug

Roche Receives FDA Priority Review for Enspryng in Thyroid Eye Disease – IL-6 Inhibitor Leverages Novel Recycling Technology for Second Indication

Company Drug

Huiyu Pharma Receives NMPA Clinical Trial Approval for HY-1016 Extended-Release Dienogest Injection – Novel Formulation Aims to Transform Endometriosis Treatment Adherence

Company Deals

RaysightMed Secures Nearly RMB 100 Million in Strategic Financing Led by State-Owned Capital – Accelerates Cardiovascular Diagnostics Scale-Up and AI Surgical Robotics Development

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.